Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 2 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Head & Neck 1 Gynecologic 1 Genitourinary 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 6 Pemetrexed 5 Carboplatin 4 Standard of Care 3 Specimen Handling 3 Practice Guidelines as Topic 3 Interviews as Topic 3 Immunoenzyme Techniques 3 Docetaxel 3 raltitrexed 2 Vincristine 2 Trabectedin 2 N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide 2 Irinotecan 2 Immunohistochemistry 2 Gemcitabine 2 Etoposide 2 Early Intervention, Educational 2 Bortezomib 2 AEG 35156 2 temsirolimus 1 sabarubicin 1 pembrolizumab 1 nintedanib 1 halofuginone 1 ascrinvacumab 1 Triptorelin Pamoate 1 Thrombopoietin 1 Theophylline 1 SB939 compound 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × nintedanib × Other solid neoplasm × Clear all

NCT02863055 2025-09-19

NEMO

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡